Derivation of xeno-free and GMP-grade human embryonic stem cells--platforms for future clinical applications |
| |
Authors: | Tannenbaum Shelly E Turetsky Tikva Tako Singer Orna Aizenman Einat Kirshberg Sophie Ilouz Nili Gil Yaniv Berman-Zaken Yael Perlman Temima Schnitzer Geva Nitshia Levy Ora Arbell Daniel Simon Alex Ben-Meir Assaf Shufaro Yoel Laufer Neri Reubinoff Benjamin E |
| |
Institution: | Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center, Jerusalem, Israel. |
| |
Abstract: | Clinically compliant human embryonic stem cells (hESCs) should be developed in adherence to ethical standards, without risk of contamination by adventitious agents. Here we developed for the first time animal-component free and good manufacturing practice (GMP)-compliant hESCs. After vendor and raw material qualification, we derived xeno-free, GMP-grade feeders from umbilical cord tissue, and utilized them within a novel, xeno-free hESC culture system. We derived and characterized three hESC lines in adherence to regulations for embryo procurement, and good tissue, manufacturing and laboratory practices. To minimize freezing and thawing, we continuously expanded the lines from initial outgrowths and samples were cryopreserved as early stocks and banks. Batch release criteria included DNA-fingerprinting and HLA-typing for identity, characterization of pluripotency-associated marker expression, proliferation, karyotyping and differentiation in-vitro and in-vivo. These hESCs may be valuable for regenerative therapy. The ethical, scientific and regulatory methodology presented here may serve for development of additional clinical-grade hESCs. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|